Related references
Note: Only part of the references are listed.How to improve long-term outcome after liver transplantation?
Francois Durand
LIVER INTERNATIONAL (2018)
International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients
Michael Charlton et al.
TRANSPLANTATION (2018)
Long-term Outcomes and Risk Factors After Adult Living Donor Liver Transplantation
Daisuke Imai et al.
TRANSPLANTATION (2018)
Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group
James M. Neuberger et al.
TRANSPLANTATION (2017)
Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial
F. Saliba et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
EASL Clinical Practice Guidelines: Liver transplantation
Patrizia Burra et al.
JOURNAL OF HEPATOLOGY (2016)
Autoimmune Liver Disease Post-Liver Transplantation: A Summary and Proposed Areas for Future Research
Catherine Edmunds et al.
TRANSPLANTATION (2016)
Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation
Jiu-Lin Song et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study
Lutz Fischer et al.
TRANSPLANTATION (2015)
Review on immunosuppression in liver transplantation
Maryam Moini et al.
WORLD JOURNAL OF HEPATOLOGY (2015)
Post-liver transplant hepatitis C virus recurrence: An unresolved thorny problem
Alberto Grassi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation
Jun-Jun Jia et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Prospective Multicenter Clinical Trial of Immunosuppressive Drug Withdrawal in Stable Adult Liver Transplant Recipients
Carlos Benitez et al.
HEPATOLOGY (2013)
Early tacrolimus exposure after liver transplantation: Relationship with moderate/severe acute rejection and long-term outcome
Manuel Rodriguez-Peralvarez et al.
JOURNAL OF HEPATOLOGY (2013)
Immunosuppression minimization vs. complete drug withdrawal in liver transplantation
Maria-Carlota Londono et al.
JOURNAL OF HEPATOLOGY (2013)
Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation
Michael R. Lucey et al.
LIVER TRANSPLANTATION (2013)
Late Acute Liver Allograft Rejection; A Study of Its Natural History and Graft Survival in the Current Era
Prem H. Thurairajah et al.
TRANSPLANTATION (2013)
Higher Tacrolimus Blood Concentration Is Related to Hyperlipidemia in Living Donor Liver Transplantation Recipients
Hong-Yu Li et al.
DIGESTIVE DISEASES AND SCIENCES (2012)
Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)
Rene Adam et al.
JOURNAL OF HEPATOLOGY (2012)
Reduced-Dose Tacrolimus with Mycophenolate Mofetil vs. Standard-Dose Tacrolimus in Liver Transplantation: A Randomized Study
K. Boudjema et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Present State of Immunosuppressive Therapy in Liver Transplant Recipients
Russell H. Wiesner et al.
LIVER TRANSPLANTATION (2011)
Evolution of Causes and Risk Factors for Mortality Post-Liver Transplant: Results of the NIDDK Long-Term Follow-Up Study
K. D. S. Watt et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Liver transplantation for autoimmune hepatitis: A single-center experience
H. Khalaf et al.
TRANSPLANTATION PROCEEDINGS (2007)
Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: Poststudy surveillance to 3 years
J. G. O'Grady et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: A meta-analysis
V. C. McAlister et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence
G Tisone et al.
JOURNAL OF HEPATOLOGY (2006)
Long-term outcome of immunosuppression withdrawal after liver transplantation
R Girlanda et al.
TRANSPLANTATION PROCEEDINGS (2005)
Immunosuppression in liver transplantation beyond calcineurin inhibitors
J Fung et al.
LIVER TRANSPLANTATION (2005)
Immunosuppressive drugs for kidney transplantation
PF Halloran
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Complete withdrawal of immunosuppression in living donor liver transplantation
F Oike et al.
TRANSPLANTATION PROCEEDINGS (2002)
End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy - Risk of development and treatment
TA Gonwa et al.
TRANSPLANTATION (2001)
Analysis of causes of death in liver transplant recipients who survived more than 3 years
J Pruthi et al.
LIVER TRANSPLANTATION (2001)
Weaning of immunosuppression in living donor liver transplant recipients
M Takatsuki et al.
TRANSPLANTATION (2001)